iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
News originally published by
GlobeNewswire— Collaboration’s objective is to evaluate the potential of a cancer therapeutic by using iDEL’s unique shuttle technology platform —
Dortmund, Germany, November 09, 2026 — iDEL Therapeutics today announced that it has entered into a research collaboration with Daiichi Sankyo (TSE: 4568) to utilize iDEL’s synthetic shuttle platform for the evaluation of a multi-drug conjugate (MDC) for select solid tumor indications.
Under the terms of the agreement, the multi-year collaboration will focus on the preclinical evaluation of a new class of MDC. The research, led by iDEL and scientists at the Daiichi Sankyo Research Institute Munich, will assess the potential of the MDC relative to an antibody-drug conjugate (ADC) with a comparable payload. Further details of the agreement were not disclosed.
“As one of the world leaders in the development of targeted cancer medicines and ADCs, Daiichi Sankyo is the ideal collaborator to support the research and future development of this novel MDC, enabled by iDEL’s synthetic shuttle technology. The collaboration is a validation of the broad potential of our modular platform,” said Marcus Kostka, PhD, Co-Founder and CEO of iDEL Therapeutics. “Our technology is being developed to explore approaches that may help mitigate challenges associated with drug uptake and endosomal entrapment.”
Beyond this collaboration, iDEL remains focused on optimizing its differentiated delivery technology to unlock previously undruggable intracellular targets, broaden therapeutic windows and increase treatment flexibility and options for patients with cancer. The company has validated its delivery approach in multiple preclinical in vivo proof-of-concept studies using small molecules, peptide and VHH payloads for intracellular targets and has translated this progress into its preclinical pipeline of MDC and single-domain antibody programs for solid tumors.
About iDEL Therapeutics
iDEL Therapeutics’ pioneering pipeline delivers drug payloads directly into the cytosol of tumor cells in patients, leveraging a unique pan-cancer uptake mechanism that achieves high intracellular drug exposure and sustained tumor retention. Our synthetic shuttle technology platform evades endosomal trapping and is compatible with both large and small molecules, including nanobodies against oncogenes and tumor-targeted cytotoxic payloads. We are focused on advancing our pipeline towards the clinic and creating scalable value through partnerships. Our mission is to transform the cancer treatment paradigm by unlocking historically undruggable intracellular targets, broadening therapeutic windows, and increasing treatment flexibility for expanded patient benefit across cancer indications.
Find more information at www.idel-tx.com.
Contact
info@idel-tx.com
+49 231 292927-00
Media requests
Trophic Communications
Marie Weickert, PhD / Adolfo Luna
+49 151 598 624 18 / +49 151 626 743 95
iDEL@trophic.eu
Attachment
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
